BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 30001747)

  • 1. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigens in Hematologic Malignancies.
    Biernacki MA; Bleakley M
    Front Immunol; 2020; 11():121. PubMed ID: 32117272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
    Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.
    Meyer M; Parpoulas C; Barthélémy T; Becker JP; Charoentong P; Lyu Y; Börsig S; Bulbuc N; Tessmer C; Weinacht L; Ibberson D; Schmidt P; Pipkorn R; Eichmüller SB; Steinberger P; Lindner K; Poschke I; Platten M; Fröhling S; Riemer AB; Hassel JC; Roberti MP; Jäger D; Zörnig I; Momburg F
    Front Immunol; 2023; 14():1294565. PubMed ID: 38239352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.
    Klar R; Schober S; Rami M; Mall S; Merl J; Hauck SM; Ueffing M; Admon A; Slotta-Huspenina J; Schwaiger M; Stevanović S; Oostendorp RA; Busch DH; Peschel C; Krackhardt AM
    Leukemia; 2014 Dec; 28(12):2355-66. PubMed ID: 24736212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of U2AF1 neoantigens in myeloid neoplasms.
    Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
    Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
    Front Immunol; 2018; 9():99. PubMed ID: 29441070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
    Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
    Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
    Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
    Front Immunol; 2020; 11():373. PubMed ID: 32226429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.
    Lorenz FKM; Ellinger C; Kieback E; Wilde S; Lietz M; Schendel DJ; Uckert W
    Hum Gene Ther; 2017 Dec; 28(12):1158-1168. PubMed ID: 28950731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
    Plewa N; Poncette L; Blankenstein T
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoantigen-targeted CD8
    Puig-Saus C; Sennino B; Peng S; Wang CL; Pan Z; Yuen B; Purandare B; An D; Quach BB; Nguyen D; Xia H; Jilani S; Shao K; McHugh C; Greer J; Peabody P; Nayak S; Hoover J; Said S; Jacoby K; Dalmas O; Foy SP; Conroy A; Yi MC; Shieh C; Lu W; Heeringa K; Ma Y; Chizari S; Pilling MJ; Ting M; Tunuguntla R; Sandoval S; Moot R; Hunter T; Zhao S; Saco JD; Perez-Garcilazo I; Medina E; Vega-Crespo A; Baselga-Carretero I; Abril-Rodriguez G; Cherry G; Wong DJ; Hundal J; Chmielowski B; Speiser DE; Bethune MT; Bao XR; Gros A; Griffith OL; Griffith M; Heath JR; Franzusoff A; Mandl SJ; Ribas A
    Nature; 2023 Mar; 615(7953):697-704. PubMed ID: 36890230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
    Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
    Front Immunol; 2021; 12():644637. PubMed ID: 33927717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
    Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
    J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.